EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Review: natural compounds as PCSK9 inhibitors for antiviral therapy

Radhwan Abdul Kareem, Hayder Naji Sameer, Zainab H Athab, Mohaned Adil, Ahmed Yaseen, Omer Qutaiba B Allela

Archives of Microbiology · 2026

DOI: 10.1007/s00203-026-05006-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Microbiology, 2026. Verfasst von Radhwan Abdul Kareem und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ahl Al Bayt University, Kerbala, Iraq. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Antiviral Agents, Biological Products, Virus Diseases. Die Arbeit nennt 199 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

From the perspective of both the host cell and the virus, cholesterol (CHO) plays a critical role during viral infection. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases the risk of cardiovascular disease by regulating plasma levels of lipoprotein(a), triglyceride-rich lipoproteins, and low-density lipoprotein cholesterol (LDL-C), and by promoting the degradation of the LDL receptor (LDLR). Emerging evidence implicates PCSK9 in the pathophysiology of several viral diseases, including human immunodeficiency virus (HIV), SARS-CoV-2, dengue virus (DENV), and hepatitis viruses. Two monoclonal antibody PCSK9 inhibitors (PCSK9i), evolocumab (Repatha®) and alirocumab (Praluent®), are approved by the Food and Drug Administration (FDA) for managing atherosclerotic risk. However, despite preclinical studies suggesting that these inhibitors and other CHO-lowering medications may interfere with viral replication, their therapeutic application as antivirals remains limited due to various restrictions. Naturally occurring compounds such as curcumin, berberine, quercetin, and polyphenols have demonstrated PCSK9-modulating and antiviral properties in preclinical models against viruses including HIV, hepatitis viruses, SARS-CoV-2, DENV, herpes simplex virus, human cytomegalovirus, and Epstein-Barr virus. Crucially, the majority of evidence for these natural substances remains preclinical, derived from in vitro and animal studies. The contribution of PCSK9 inhibition to the reported antiviral effects remains unclear, as pleiotropic mechanisms may be involved. Therefore, rather than being clinically proven substitutes for licensed PCSK9-targeted treatments, these molecules should be considered experimental or maybe supplementary medicines. This review examines the current preclinical evidence for natural inhibitors of PCSK9 and their antiviral properties, discusses clinical assessments to date, and considers the potential future role of naturally occurring PCSK9i in antiviral development, acknowledging the substantial research gaps that remain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsAntiviral AgentsBiological ProductsVirus DiseasesHumansProprotein Convertase 9AnimalsSARS-CoV-2Antibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Lipid-lowering drugsNatural compoundsPCSK9Viral infection

Substanzen

PCSK9 InhibitorsAntiviral AgentsProprotein Convertase 9PCSK9 protein, humanBiological ProductsAntibodies, Monoclonal, Humanizedalirocumabevolocumab

Autor:innen und Institutionen

  • Ahl Al Bayt University, Kerbala, Iraq.
  • Collage of Pharmacy, National University of Science and Technology, Dhi Qar, 64001, Iraq.
  • Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
  • Pharmacy college, Al-Farahidi University, Baghdad, Iraq.
  • Gilgamesh Ahliya University, Baghdad, Iraq.
  • College of Pharmacy, Alnoor University, Nineveh, Iraq. omerallela@alnoor.edu.iq.

Zitieren

APA

Kareem, R. A., Sameer, H. N., Athab, Z. H., Adil, M., Yaseen, A., & Allela, O. Q. B. (2026). Review: natural compounds as PCSK9 inhibitors for antiviral therapy. Archives of Microbiology. https://doi.org/10.1007/s00203-026-05006-1

Vancouver

Kareem RA, Sameer HN, Athab ZH, Adil M, Yaseen A, Allela OQB. Review: natural compounds as PCSK9 inhibitors for antiviral therapy. Archives of Microbiology. 2026. doi:10.1007/s00203-026-05006-1

BibTeX
@article{Kareem2026,
  author = {Kareem, Radhwan Abdul and Sameer, Hayder Naji and Athab, Zainab H and Adil, Mohaned and Yaseen, Ahmed and Allela, Omer Qutaiba B},
  title = {Review: natural compounds as PCSK9 inhibitors for antiviral therapy},
  journal = {Archives of Microbiology},
  year = {2026},
  doi = {10.1007/s00203-026-05006-1}
}
Kostenlos starten →